For more than 30 years, Eurofins NTD, LLC. has pioneered the research and development of prenatal screening protocols for open neural tube defects, Down syndrome, trisomy 18 and trisomy 13. Today, Eurofins NTD, LLC. serves universities, medical centers, hospitals, laboratories, obstetricians and maternal fetal medicine specialists worldwide; providing risk assessment services that help health care professionals and patients make more informed medical decisions.
Eurofins NTD, LLC. maintains one of the largest maternal serum banks worldwide. Its menu of risk assessment services includes the First Trimester Screen | Fß (free Beta hCG/PAPP-A/NT) protocol, the First Trimester Screen | Fß protocol with Nasal Bone Assessment, and the Instant Risk Assessment program. Eurofins NTD, LLC. was one of the world’s first clinical laboratories to provide an alpha-fetoprotein (AFP) screening program, a service that identifies risk for open neural tube defects (ONTDs), which it still provides today.
Annually, Eurofins NTD, LLC processes hundreds of thousands of maternal blood specimens using specially designed analytical workflow cycles and immunoassay systems that ensure accurate testing and documentation, and efficient specimen handling and reporting.
To learn more about Eurofins NTD, LLC. and its innovative risk assessment testing protocols, Contact Us today.
DISCLAIMER: Pursuant to applicable federal and/or state laboratory requirements, Eurofins NTD, LLC has established and verified the accuracy and precision of its testing services. Tests are developed and performance characteristics determined by Eurofins NTD, LLC. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.